Projects / Programmes
Histološki in imunohistokemični napovedi dejavniki pri karcinomu dojke v stadiju I (Slovene)
| Code |
Science |
Field |
Subfield |
| 3.04.00 |
Medical sciences |
Oncology |
|
| Code |
Science |
Field |
| B200 |
Biomedical sciences |
Cytology, oncology, cancerology |
breast cancer, pathology, immunohistochemistry, prognosis
Researchers (17)
Organisations (1)
| no. |
Code |
Research organisation |
City |
Registration number |
No. of publicationsNo. of publications |
| 1. |
0302 |
Institute of Oncology Ljubljana |
Ljubljana |
5055733000 |
15,468 |
Abstract
Although prognosis of patients with stage I (T1N0M0) breast carcinoma is generally favorable, approximately 20% of these will at some time develop distant metastases and eventually die of disease. Recent meta-analyses of published data indicate that even the group of patients with early breast carcinoma may benefit from systemic chemotherapy and/or hormonal therapy; it is however clear that the large majority of these patients would be cured even without adjuvant systemic treatment. Thus the major change in the recent period has been from the question of who should be treated by chemotherapy and/or hormonal therapy to the question of who should not be so treated. Unfortunately, there is no general agreement as to which factors are most helpful in identifying, among patients with stage I breast carcinoma, those with minimal risk of developing metastasis and dying of disease. The role of tumor size is generally accepted and several studies have shown the prognostic importance of histologic type, grade and presence of vascular invasion. Numerous additional biologic tumor markers have recently been studied; however, this was done mostly in relatively small and heterogeneous groups of patients with limited follow-up information, and none of these markers has gained general clinical acceptance. We will retrospectively study a group of approximately 250 patients with stage I breast carcinoma who were followed for 15 years and investigate several histologic features (histologic type, histologic grade and presence of vascular invasion) as well as several new markers (p53, bcl-2 and c-erbB-2, proliferation marker MIB-1, CEA, estrogen and progesterone receptors and angiogenesis) that can be assessed by immunohistochemistry on archival paraffin-embedded material. Their relative value for prediction of disease progression and cancer-related deaths will be evaluated. We expect that combination of the investigated features will help to identify a subgroup of stage I breast cancer patients with minimal risk of tumor progression and/or death and no need for systemic treatment.
